Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Regeneron Pharmaceuticals ( REGN) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole was unchanged today. By the end of trading, Regeneron Pharmaceuticals rose $4.16 (3%) to $144.90 on light volume. Throughout the day, 506,373 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 712,100 shares. The stock ranged in a price between $142.24-$146.23 after having opened the day at $142.63 as compared to the previous trading day's close of $140.74. Other companies within the Health Care sector that increased today were: CombiMatrix Corporation ( CBMX), up 32.2%, Idera Pharmaceuticals ( IDRA), up 21.6%, Sarepta Therapeutics ( SRPT), up 19.3%, and Myrexis ( MYRX), up 17.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. Regeneron Pharmaceuticals has a market cap of $13 billion and is part of the drugs industry. The company has a P/E ratio of 69.9, above the S&P 500 P/E ratio of 17.7. Shares are up 148.3% year to date as of the close of trading on Friday. Currently there are nine analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Clovis Oncology ( CLVS), down 41.8%, Galena Biopharma ( GALE), down 31%, Omeros Corporation ( OMER), down 15%, and Progenics Pharmaceuticals ( PGNX), down 14.1%, were all laggards within the health care sector with Vertex Pharmaceuticals ( VRTX) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

If you liked this article you might like

Regeneron Pharmaceuticals Ready to Make All-Time Highs

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

If It's Not Earnings News, It's Amazon Competition: Jim Cramer's Best Blog

Electronic Arts, Activision Blizzard and Take-Two Interactive: 'Mad Money' Lightning Round